Scarica l'app Stockscreener
1.96
7.98%
-0.17
Pre-mercato:
1.96
Precedente Chiudi:
$2.13
Aprire:
$2.13
Volume 24 ore:
1.93M
Relative Volume:
1.62
Capitalizzazione di mercato:
$157.92M
Reddito:
$52.74M
Utile/perdita netta:
$-6.60M
Rapporto P/E:
-23.20
EPS:
-0.0845
Flusso di cassa netto:
$-13.63M
1 W Prestazione:
-7.55%
1M Prestazione:
-8.84%
6M Prestazione:
-17.65%
1 anno Prestazione:
-30.99%
Intervallo 1D:
$1.925
$2.1725
Intervallo di 1 settimana:
$1.925
$2.1725
Portata 52W:
$1.32
$3.19
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Nome
Protalix BioTherapeutics Inc.
Settore
Industria
Telefono
972 4 988 9488
Indirizzo
2 Snunit Street, Science Park PO Box 455, Karmiel
Compare PLX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
1.96 | 157.92M | 52.74M | -6.60M | -13.63M | -0.0845 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-17 | Reiterato | Rodman & Renshaw | Buy |
| 2016-04-04 | Iniziato | Rodman & Renshaw | Buy |
| 2015-04-23 | Aggiornamento | Jefferies | Hold → Buy |
| 2014-11-12 | Reiterato | R. F. Lafferty | Buy |
| 2014-01-24 | Iniziato | R. F. Lafferty | Buy |
| 2012-05-02 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | Reiterato | Oppenheimer | Outperform |
| 2012-04-30 | Downgrade | Auriga | Buy → Hold |
| 2011-10-13 | Iniziato | Morgan Joseph | Hold |
| 2011-03-17 | Downgrade | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | Reiterato | Oppenheimer | Outperform |
| 2010-10-14 | Reiterato | UBS | Buy |
| 2009-12-02 | Reiterato | Hapoalim | Outperform |
| 2009-09-22 | Iniziato | Canaccord Adams | Buy |
| 2009-09-02 | Iniziato | Hapoalim | Outperform |
| 2008-12-01 | Reiterato | Oppenheimer | Outperform |
| 2008-03-11 | Iniziato | UBS | Buy |
| 2007-11-20 | Iniziato | CIBC Wrld Mkts | Sector Outperform |
Mostra tutto
Protalix BioTherapeutics Inc. Borsa (PLX) Ultime notizie
Protalix BioTherapeutics (PLX) sets 2026 director, pay and stock plan votes - Stock Titan
Protalix says EU panel recommended a new dosing regimen for Fabry disease therapy - MSN
Protalix CFO updates Form 3 share and option holdings | PLX Insider Trading - Stock Titan
PLX News | PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) - ChartMill
Protalix BioTherapeutics (NYSE:PLX) Stock Price Down 2.2%Here's Why - MarketBeat
Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025 - Quantisnow
Protalix: Elfabrio Struggles Against Oral Competition (NYSE:PLX) - Seeking Alpha
Aug Chart Watch: Is Protalix BioTherapeutics Inc currently under institutional pressure2026 Growth vs Value & Fast Moving Stock Watchlists - baoquankhu1.vn
PLX Stock Price, Quote & Chart | PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) - ChartMill
Is Protalix (PLX) Stock entering maturity stage | Price at $2.26, Up 3.20%Senior Analyst Forecasts - Xã Vĩnh Công
Targets Report: What is Protalix BioTherapeutics Incs valuation compared to sectorIPO Watch & Risk Controlled Daily Trade Plans - baoquankhu1.vn
PLX Technical Analysis & ETF Price Forecast - Intellectia AI
EBIT per share of Protalix Biotherapeutics, Inc. – SWB:PBDA - TradingView
PLX SEC FilingsProtalix Biother 10-K, 10-Q, 8-K Forms - Stock Titan
PLX Q4 Earnings: Misses Estimates by $0.08 - Cổng thông tin điện tử Tỉnh Sơn La
Protalix Earnings Call: EU Win, Cash Boost, Trade-Offs - The Globe and Mail
PLX|Protalix Biotherapeutics Inc|Price:2.150|Chg%:-0.04 - TradingKey
MACD Signal: Is Protalix BioTherapeutics Inc a top pick in the sector2026 Trading Volume Trends & Weekly High Return Forecasts - baoquankhu1.vn
Protalix targets $78M–$83M 2026 revenue with EU milestone, advancing PRX-115 - MSN
MAK Capital, Michael Kaufman report 3.62M‑share PLX stake (PLX) - Stock Titan
Aug Opening: What is Protalix BioTherapeutics Incs valuation compared to sector2026 Retail Activity & AI Based Trade Execution Alerts - baoquankhu1.vn
Volume Summary: Will Protalix BioTherapeutics Inc benefit from rising consumer demandPortfolio Risk Report & Long Hold Capital Preservation Tips - baoquankhu1.vn
Analyst Downgrade: Should I add Protalix BioTherapeutics Inc stock to my portfolio2026 Top Gainers & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance (NYSE:PLX) - Seeking Alpha
Zacks Research Has Bullish Estimate for PLX FY2026 Earnings - MarketBeat
HC Wainwright Issues Negative Outlook for PLX Earnings - marketbeat.com
Can Protalix BioTherapeutics Inc lead its sector in growth2026 Growth vs Value & Weekly Top Gainers Alerts - baoquankhu1.vn
If You Invested $1,000 in Protalix Biother (PLX) - Stock Titan
A Look At Protalix BioTherapeutics (PLX) Valuation After Elfabrio Dosing Approval And Updated 2026 Revenue Guidance - Sahm
Research Analysts Issue Forecasts for PLX FY2026 Earnings - MarketBeat
Stock Market Recap: Is Cirrus Logic Inc forming a bullish divergenceRate Hike & High Win Rate Trade Alerts - baoquankhu1.vn
PLX: HC Wainwright & Co. Reiterates Buy Rating with $12 Target | - GuruFocus
Protalix BioTherapeutics (NYSE:PLX) Receives "Buy" Rating from HC Wainwright - MarketBeat
Protalix BioTherapeutics (PLX) TTM Loss Challenges Bullish Profitability Narratives After FY 2025 Results - simplywall.st
Protalix BioTherapeutics Inc (PLX) Q4 2025 Earnings Call Highlig - GuruFocus
PLX: 2025 Full Year Results - Yahoo Finance
Protalix BioTherapeutics (PLX) Misses Earnings Estimates, Projec - GuruFocus
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results - Finviz
Protalix: Overview of Fourth Quarter Financial Results - Bitget
Protalix (PLX) 2025 10-K details Elfabrio expansion and PRX-115 gout program - Stock Titan
Protalix BioTherapeutics 2025 Annual Report: Innovative Plant Cell-Based Therapeutics, Pipeline, Intellectual Property, and Regulatory Overview - Minichart
Earnings call transcript: Protalix misses EPS, beats revenue in Q4 2025 By Investing.com - Investing.com South Africa
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025 - Yahoo Finance
PLX: EU approval of Elfabrio's four-week dosing drives revenue growth and strengthens cash position - TradingView
Earnings call transcript: Protalix misses EPS, beats revenue in Q4 2025 - Investing.com
Recap Report: Can Protalix BioTherapeutics Inc keep up with sector leaders2026 Technical Overview & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Protalix BioTherapeutics Financial Results: Quarterly & Annual ReportNews and Statistics - IndexBox
Protalix BioTherapeutics 2025 10-K: $52.7M Revenue, $(6.6)M Net Loss - TradingView
PLX: 2025 revenue reached $52.7M with a net loss of $6.6M as R&D spending increased sharply - TradingView
Protalix Biotherapeutics Reports Fiscal Year 2025 Financial And Business Results - TradingView
Protalix BioTherapeutics Inc. Azioni (PLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):